Results 101 to 110 of about 117,919 (266)

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

British Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo, Veronica Casale, Roberta d'Emmanuele di Villa Bianca, Valentina Vellecco, Mariarosaria Bucci   +4 more
wiley   +1 more source

Triptolide capsule enables proteinuria reduction and renal stabilization in advanced alport syndrome beyond standard therapy

Rheumatology &Autoimmunity, EarlyView.
Zhuo‐ran Song, Na Li, Yang Li, Hong Zhang, Xu‐jie Zhou   +4 more
wiley   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

Five Advances in the Last 50 Years That Have Impacted Endocrine Surgery

World Journal of Surgery, EarlyView.
Matilda Anneback, Priya H. Dedhia, Aimee Di Marco, Els Nieveen van Dijkum, Julie A. Miller, Janice L. Pasieka   +5 more
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

The lung is more than an organ of gas exchange: immunocompetency, platelets and implications for drug discovery

British Journal of Pharmacology, EarlyView.
Abstract The lungs have for a long time been recognised as having pharmacological significance as a specific organ to modulate the pharmacokinetics of endogenous substances needed to maintain homeostasis. The lungs are therefore the site of action of certain drugs that act on these homeostatic processes, resulting in systemic effects on the ...
Simon C. Pitchford
wiley   +1 more source

A Ten Year Overview of Adrenal Vein Sampling in Croatia: Insights and Outcomes

Clinical Endocrinology, EarlyView.
ABSTRACT Background Adrenal vein sampling (AVS) is the gold standard for subtype differentiation in primary aldosteronism (PA), yet it remains technically demanding and resource intensive. However, data on long‐term performance, learning curves, and concordance with imaging in real‐world clinical practice are limited.
Karin Zibar Tomsic, Ana Marija Alduk, Elvira Kresic, Ivana Kraljevic, Darko Kastelan   +4 more
wiley   +1 more source

Advanced machine learning-based screening for primary aldosteronism with plasma steroids, potassium, and renin. [PDF]

NPJ Digit Med
Zhang W, Pamporaki C, Jäkel R, Constantinescu G, Peitzsch M, Schulze M, Yang J, Horvath AR, Müller-Pfefferkorn R, Williams TA, Reincke M, Beuschlein F, Fuss CT, Hahner S, Eisenhofer G.   +14 more
europepmc   +1 more source

Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre‐Specified Secondary Analysis of the TVFR Trial

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Hyponatraemia is a common electrolyte disorder often driven by excess arginine vasopressin (AVP). Copeptin is a stable surrogate marker co‐secreted with AVP. It is unclear whether treatment of hyponatraemia with tolvaptan, an AVP‐V2 receptor antagonist, impacts copeptin.
Annabelle M. Warren, Kay Weng Choy, Rudolf Hoermann, Nicholas Russell, Mathis Grossmann   +4 more
wiley   +1 more source

A Diagnostic Pitfall of Primary Aldosteronism Presenting as Recurrent Quadriparesis: A Case Report. [PDF]

Clin Case Rep
Shakir J, Benyamin J, Iqbal MU, Sohail A, Mazhar A, Abdullah HM, Habib E, Danaf N.   +7 more
europepmc   +1 more source